New Major Pharmaceutical Client

RNS Number : 9521C

Physiomics PLC

26 January 2018

 

26^th January 2018

Physiomics plc

("Physiomics") or ("the Company")

New Major Pharmaceutical Client

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has been awarded a contract by a new major pharmaceutical client.  The project, which is expected to be completed during the Company's current financial year involves the use of Physiomics' Virtual Tumour technology in a pre-clinical setting and its value is approximately £35k.

Physiomics' Virtual Tumour is a sophisticated computer model that simulates tumour cell division and predicts the effect of different anti-cancer regimes to support pre-clinical and clinical oncology development programs. Virtual Tumour helps customers to balance efficacy and toxicity and to prioritise the most effective drug combinations while reducing time and cost.

Jim Millen, CEO said: "We are delighted to be working with a significant new client.  If this initial project is successful, we would hope to develop a longer-term relationship."

Enquiries:

Physiomics plc                                                  

Dr Jim Millen, CEO

[phone]

WH Ireland Limited (nomad)

Katy Mitchell

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Eli Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

 

END

 

 

CNTXELFLVFFBBBD